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The rat and rabbit transport IgA from blood to bile by a highly efficient transcellular pathway mediated 
by secretory component (SC). Other mammals do not express SC on liver hepatocytes, but they do transport 
a small amount of IgA to bile. In the first part of this study, human polymeric IgA was radiolabeled and 
depleted of SC binding activity by successive affmity adsorption. Transport of this preparation intact to 
rat bile was 4%. but was reduced to 2% when 50 mg unlabeled asialoglycoprotein was preadministered. 
The 2:< decline corresponds to the percent of asiaio-orosomucoid iverted to bile from the lysosomal path- 
way. In guinea-pigs, missorting of asialo-orosomucoid intact to bile was 10% of the injected dose. Transport 
of normal human IgA to bile was l-2%, even though guinea-pigs do not express SC in the liver. Excess 
unlabeled asialofetuin reduced the transport of asialo-orosomucoid by IO-fold and IgA by 6-fold. This dem- 
onstrates that the asialoglycoprotein receptor can mediate transport of IgA to bile in small amounts, but 
that this transport may be only a biological artifact resulting from limited fidelity of intracellular protein 
sorting. 
Immunoglobulin A Asialoglycoprotein receptor Secretory component Receptor-mediated endocytosis 
Transport to bile 
1. INTRODUCTION [B-l 11. SC is specific for polymeric immunoglob- 
ulins: other proteins (including ASG) do not bind. 
The liver hepatocyte takes up many proteins A remarkable feature of the IgA pathway in the 
from blood by receptor-mediated endocytosis. liver is that its expression is restricted to only a few 
Most proteins, such as desialylated glycoproteins mammalian species. Little SC is expressed on nor- 
(ASG) [l-3], are processed primarily by degrada- mal human hepatocytes [12]; only -2% of in- 
tion in lysosomes. There is only one known exam- travenously injected IgA is transported to human 
ple for quantitative delivery of the ligand intact to bile in a 24-h period [ 13,141. Part of this transport 
bile: the IgA transport system, originally described occurs through bile duct cells [15]; the remainder 
in the rat [4-61. Polymeric IgA is cleared from may occur through hepatocytes via a pathway not 
blood within a few minutes, and essentially all of mediated by SC [16]. Biochemical features of this 
the receptor-bound ligand appears in bile about 30 alternative pathway, and complete assessment of 
min later [7]. The receptor for this pathway is the its physiological importance, have remained 
membrane analogue of secretory component elusive. 
Abbreviations: ASFet, asialofetuin; ASG, asialoglyco- 
protein; ASOr, asialo-orosomucoid; BH, Bolton and 
Hunter (labeled); HPLC, high pressure liquid chromato- 
graphy; IgA, immunoglobulin A; SC, secretory compo- 
nent 
Protein sorting 
Recently, Stockert et al. [17] provided the im- 
portant observation that human IgA can bind to 
the ASG receptor in vitro. This is relevant, because 
a small proportion of specifically endocytosed 
ASG is missorted and delivered instead to bile [7]. 
These two observations prompt the question of 
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whether IgA can use the ASG receptor to get to 
bile. 
2. METHODS 
Human polymeric IgAr was isolated from 
myeloma serum by ammonium sulfate and oc- 
tanoic acid precipitation [ 181, followed by chroma- 
tography on DEAE cellulose, and then Sepharose 
6B. Rat polymeric IgA was isolated using a similar 
protocol, from the ascites fluid of plasmacytoma 
line IR22, kindly provided by H. Bazin of the 
University of Louvain, Brussels. Human SC was 
prepared by affinity chromatography of colostral 
whey on IgM Sepharose [191. Human orosomucoid 
was the generous gift of the American Red Cross 
Blood Services Laboratory, Bethesda, MD. It was 
desialylated by mild acid hydrolysis [20]. Fetuin 
was prepared from fetal calf serum by the method 
of Spiro [20], or purchased from Sigma, St. Louis. 
Fetuin was desialylated by incubation overnight at 
37°C with agarose-linked neuraminidase [7]. 
IgA and ASOr were radioiodinated using iodine 
monochloride [21] or the Bolton and Hunter (BH) 
reagent [22]. Details of the labeling protocols, 
removal of free radioisotope, and characterization 
have been given previously [7]. To generate pre- 
parations of IgA devoid of SC-binding activity, 
labeled IgA was incubated in 1 ml of phosphate- 
buffered saline (pH 7.4), containing 1 mg human 
albumin and 0.15 ml SC-Sepharose (1 mg SC/ml 
Sepharose 4B) for 12 h at room temperature on a 
rotator. Supernatants were passaged to fresh SC- 
Sepharose for further adsorption. Final products 
were redialysed against 0.9% saline before use in 
transport studies. Fractional SC binding activities 
were determined in vitro by incubating trace 
amounts of IgA preparations with 15 ~1 SC- 
Sepharose under the same conditions. SC-non- 
adherent human IgA was >90% precipitable with 
anti-human IgA Sepharose. 
Transport studies were conducted in male 
Wistar rats (250-350 g) and albino guinea-pigs 
(500-650 g). Each rat was anesthetized with 
sodium pentobarbital, the right femoral vein was 
cannulated for sample injection using PE-10 In- 
tramedic polyethylene tubing (Clay Adams, Par- 
sippany, NJ), and the bile duct was cannulated 
through an abdominal mid-line incision using 
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PE-50 tubing. Each guinea-pig was anesthetizec 
with the volatile anesthetic methoxyflurane (‘Pen 
trane’, Abbott Laboratories, Montreal). The left 
jugular vein was cannulated with PE-10 tubing, the 
bile duct was cannulated with PE-50 tubing so that 
the tip of the cannula was within 0.5 cm of the 
liver, and the gall bladder was ligated. 50 mg of 
potential competitor (Fet or ASFet) in 1 ml 0.9% 
saline was infused over 10 min through the venous 
cannula, and was followed immediately by the 
radioactive sample. 10 min bile aliquots were col- 
lected for 3 h. Activity transported was corrected 
by computer for isotopic overlap and radioactive 
decay. Each determination in the kinetic profiles is 
plotted at the median of the interval over which the 
sample was collected, after correction for the 
volume of the cannula. 
To determine the proportion of transported ac- 
tivity present in bile as protein-bound label, 0.5 ml 
of pooled bile from each animal was passed over 
an LKB (Uppsala) SW-3000 gel filtration HPLC 
column in Tris-buffered saline (pH 7.1). 2-ml frac- 
tions were collected for counting. Because of the 
high bile flow rate and low level of IgA transport 
in guinea-pigs, the proportion of protein-bound 
label in bile aliquots from these experiments was 
determined by precipitation with an equal volume 
of 0.5% phosphotungstic acid in 1 N HCl. The ab- 
solute percentage of injected material transported 
to bile as intact protein was thus defined as the 
product of the total activity transported and the 
proportion which was protein-bound in the ana- 
lysed sample. 
3. RESULTS AND DISCUSSION 
We have shown previously that ASFet does not 
compete with the SC-mediated transport of rat IgA 
to bile [7]. However, the presence of galactose- 
terminated oligosaccharides in the hinge region of 
human IgAt [23] could give the human protein bet- 
ter access to transport pathways mediated by the 
ASG receptor. To determine whether binding to 
this alternative receptor could provide a substitute 
mechanism for IgA transport to bile, we isolated 
the subfraction of human IgA deficient in SC bind- 
ing. Labeled human IgA polymers were adsorbed 
serially over 5 fresh aliquots of SC-Sepharose. 
Specific SC binding activity of the product, com- 
pared with the starting preparation, had been 
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reduced lo-fold. When injected into rats, >75% 
of the SC-non-adherent human IgA was cleared 
from blood within 10 min, and -4% was trans- 
ported to bile as intact protein. 
To determine whether the ASG receptor played 
a role in the hepatic processing of this preparation, 
experiments were conducted in which the injection 
of the test ligand was preceded by 50 mg of an 
unlabeled potential competing glycoprotein: either 
native fetuin, or ASFet (fig.1). Native fetuin pro- 
vided a negative control for inhibition: it has no 
detectable effect on any of the pathways tested in 
this study [7]. Compared to the control, excess 
ASFet had little relative impact on the SC-mediated 
pathway: the total proportion of SC-binding 
human or rat IgA transported to bile was unaf- 
fected. In contrast, ASFet was able to reduce by 
half the small amount of intact protein reaching 
bile from injections of labeled ASOr (another 
desialylated glycoprotein, otherwise unrelated). 
Most importantly, excess ASFet also reduced by 
half the low-level transport of the IgA preparation 
that had been depleted of SC-binding activity. The 
INHIBITOR Fet ASH 
LIGANO rat IgA 
2 3 4 4 4 4 
Fet ASFet Fe, ASFN Fet ASFet 
III 
ASOr human IgA non-SC-bmdmg 
human IgA 
Fig. 1. Intact protein transported to rat bile. Experiments 
in which the radioligand was preceded by 50 mg un- 
labeled ASFet are compared to parallel control ex- 
periments with native fetuin (Fet). Note the use of the 
geometric scale. Bile was collected for 150 min after in- 
jection of the radioactive probe, and analysed by HPLC 
for protein-bound label. Results are mean of 2-4 
animals in each group (uncertainty shown is SE, or range 
where n = 2). p values were calculated using the l-sided 
Student’s ?-test for equal means. 
IgA still transported presumably reflects residual 
SC-binding activity that had survived the adsorp- 
tion procedure. 
These results indicate that circulating human 
IgA can be captured efficiently by the ASG recep- 
tor in the rat, and that 2% of an injected dose can 
use this receptor to get to bile. This is about the 
same proportion that appears in bile intact follow- 
ing a trace injection of ASG, and presumably oc- 
curs by the same mechanism: missorting of protein 
entering the lysosomal pathway [7]. The propor- 
tion transported is small: IgA without an SC bind- 
ing site has no special capacity to avoid en masse 
the fate of other proteins entering the degradative 
route. In order to achieve substantial transcellular 
transport, the ability to bind SC is apparently 
essential. 
The next objective was to evaluate the ability of 
the ASG receptor to mediate IgA transport in a 
species that did not express SC on liver paren- 
chymal cells. We chose to use guinea-pigs, which 
are capable of transporting only - 2% of injected 
IgA to bile [24,25]. To demonstrate the efficacy of 
the inhibition protocol, experiments were con- 
ducted using ICI-labeled ASOr, which is trans- 
ported to bile primarily as intact protein, and BH- 
ASOr, which releases catabolites into bile follow- 
ing lysosomal degradation [7]. Results are shown 
in fig.2. Both the major pathway leading to 
lysosomal degradation, and the minor pathway 
releasing intact ASOr into bile, were impaired 
substantially by prior ASFet administration. Both 
pathways are thus mediated by a receptor specific 
for ASG. 
In the experiment of primary interest, pread- 
ministration of ASFet successfully inhibited the 
biliary transport of unfractionated human IgA 
(fig.2): both in terms of total radiolabel, and label 
that was protein bound. The total proportion 
transported over the course of the experiment was 
reduced 6-fold (fig.3), almost as much as the 
relative reduction of intact ASOr transport. Thus, 
the ASG receptor provides access of IgA to bile, ir- 
respective of the absence of the SC-mediated 
transcellular pathway. The amount transported is 
small, and does not exceed that of other glycopro- 
teins with terminal galactose residues. However, 
transport via this receptor does account for most 
of the IgA that is transported from blood to bile in 
this species. 
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-1 INHIBITOR Fet 1 INHIBITOR ASFet 
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q radiolabel transported 
from ICI-IgA 
Fig.2. Kinetic profiles of appearance of radiolabel in the 
bile of individual guinea-pigs. 50 mg Fet or ASFet was 
administered intravenously, followed immediately by 
the radiolabeled probe: ICI-ASOr (mainly reflecting 
transport of intact ASOr), BH-ASOr (reflecting 
lysosomal degradation of ASOr by biliary release of 
catabolites), or ICI-IgA. Radiolabel in bile bound to in- 
tact IgA was determined for individual IO-min aliquots 
by acid precipitation. 
It is obviously difficult to obtain direct ex- 
perimental proof that the ASG receptor mediates 
IgA transport to bile in man. However, it is evident 
from this study that binding to a receptor primarily 
mediating degradation, followed by the apparently 
universal occurrence of intracellular missorting, 
may provide the hitherto undescribed mechanism 
for IgA to get to bile. The low-level diversion from 
lysosomes to the bile canaliculus provides impor- 
tant clues to the steps involved in ligand sorting, 
and is therefore of continuing interest. However, 
in our opinion, this explanation dininishes the 
likelihood that plasma to bile transport of an- 
tibody provides a bone fide contribution to muco- 
sal immunity in man. Low-level appearance of 
INHIBITOR Fet ASFet Fet ASFet 
L , I I 
LIGAND ASOr human IgA 
Fig.3. Intact protein transported to guinea-pig bile. The 
radioligand was injected just following a 50 mg dose of 
unlabeled Fet or ASFet. Results are the mean (? range) 
of 150-min collections of bile from 2 animals in each 
group. Differences within each pair are significant at 
p<o.os. 
other proteins in bile - insulin [26], epidermal 
growth factor [27], hemoglobin [28,29], enzymes 
[30-341, and apolipoproteins [35,36] - may also be 
the fortuitous result of protein missorting: intrigu- 
ing, but of minimal physiological impact. 
ACKNOWLEDGEMENT 
This study was supported by grants from the 
Medical Research Council of Canada. 
REFERENCES 
[1] Ashwell, G. and Harford, J. (1982) Annu. Rev. 
Biochem. 5 1, 53 l-554. 
[2] Stockert, R.J. and Morel], A.G. (1983) Hepatology 
3, 150-151. 
[3] Schwartz, A.L. (1984) CRC (Chem. Rubber Co.) 
Crit. Rev. Biochem. 16, 207-233. 
[4] Jackson, G.D.F., Lemaitre-Coelho, I., Vaerman, 
J.-P., Bazin, H. and Beckers, A. (1978) Eur. J. 
Immunol. 8, 123-126. 
[5] Orlans, E., Peppard, J., Reynolds, J. and Hall, 
J.G. (1978) J. Exp. Med. 147, 588-592. 
88 
Volume 182, number 1 FEBS LETTERS March 1985 
[6] Fisher, M.M., Nagy, B., Bazin, H. and Under- [21] Helmkamp, R.W., Goodland, R.L., Bale, W.F., 
down, B.J. (1979) Proc. Natl. Acad. Sci. USA 76, Spar, I.L. and Mutschler, L.E. (1960) Cancer Res. 
2008-2012. 20, 1495-1500. 
[7] Schiff, J.M., Fisher, M.M. and Underdown, B.J. 
(1984) J. Cell Biol. 98, 79-89. 
[8] Socken, D.J., Jeejeebhoy, K.N., Bazin, H. and 
Underdown, B.J. (1979) J. Exp. Med. 150, 
1538-1548. 
[22] Bolton, A.E. and Hunter, W.M. (1973) Biochem. 
J. 133, 529-539. 
[23] Baenziger, J. and Kornfeld, S. (1974) J. Biol. 
Chem. 249, 7270-7281. 
[9] Orlans, E., Peppard, J., Fry, J.F., Hinton, R.H. 
and Mullock, B.M. (1979) J. Exp. Med. 150, 
1577-1581. 
[24] Hall, J.G., Gyure, L.A. and Payne, A.W.R. (1980) 
Immunology 41, 899-902. 
[lo] Mostov, K.E. and Blobel, G. (1982) J. Biol. Chem. 
257, 11816-11821. 
[II] Geuze, H.J., Slot, J.W., Strous, G.J.A.M., 
Peppard, J., von Figura, K., Hasilik, A. and 
Schwartz, A.L. (1984) Cell 37, 195-204. 
[12] Delacroix, D.L., Courtoy, P.J., Rahier, J., Reyn- 
aert, M., Vaerman, J.-P. and Dive, C. (1984) 
Gastroenterology 86, 521-53 1. 
[ 131 Delacroix, D.L., Hodgson, H.J.F., McPherson, 
A., Dive, C. and Vaerman, J.-P. (1982) J. Clin. 
Invest. 70, 230-241. 
[25] Vaerman, J.-P., Lemaitre-Coelho, I.M., Limet, 
J.N. and Delacroix, D.L. (1982) in: Recent Ad- 
vances in Mucosal Immunity (Strober, W. et al. 
eds), pp. 233-250, Raven Press, New York. 
[26] Terris, S. and Steiner, D.F. (1976) J. Clin. Invest. 
57, 885-896. 
[27] Burwen, S.J., Barker, M.E., Goldman, I.S., 
Hradek, G.T., Raper, S.E and Jones, A.L. (1984) 
J. Cell Biol., in press. 
[ 141 Dooley, J.S., Potter, B.J., Thomas, H.C. and 
Sherlock, S. (1982) Hepatology 2, 323-327. 
[ 151 Nagura, H., Smith, P.D., Nakane, P.K. and 
Brown, W.R. (1981) J. Immunol. 126, 587-595. 
[16] Delacroix, D.L. and Vaerman, J.-P. (1983) Ann. 
N.Y. Acad. Sci. 409, 383-401. 
[ 171 Stockert, R. J., Kressner, M.S., Collins, J.C., 
Sternlieb, I. and Morell, A.G. (1982) Proc. Natl. 
Acad. Sci. USA 79, 6229-6231. 
[18] Fine, J.M. and Steinbuch, M. (1970) Rev. Eur. 
Etud. Clin. Biol. 15, 1115-1121. 
[19] Underdown, B.J., DeRose, J., Koczekan, K., 
Socken, D. and Weicker, J. (1977) Immunochemis- 
try 14, 111-118. 
[28] Hinton, R.H., Dobrota, M. and Mullock, B.M. 
(1980) FEBS Lett. 112, 247-250. 
[29] Limet, J.N., Quintart, J., Otte-Slachmuylder, C. 
and Schneider, Y.-J. (1982) Acta Biol. Med. Ger. 
41, 113-124. 
[30] Rohr, G., Kern, H. and Scheele, G. (1981) Nature 
292, 470-472. 
[31] Grant, D.A.W. and Fleming, S.C. (1981) Biosci. 
Reports 1, 765-770. 
[32] Warnes, T.W., Hine, P., Kay, G. and Smith, A. 
(1981) Gut 22, 493-498. 
[20] Spiro, R.G. (1960) J. Biol. Chem. 235, 2860-2869. 
[33] Russel, F.G.M., Weitering, J.G., Oosting, R., 
Groothuis, G.M.M., Hardonk, M.J. and Meijer, 
D.K.F. (1983) Gastroenterology 85, 225-234. 
[34] Sewell, R.B., Barham, S.S. and LaRusso, N.F. 
(1983) Gastroenterology 85, 1146-l 153. 
[35] Lafont, H., Lechene de la Porte, P., Vigne, J.L. 
and Nalbone, G. (1982) Cytobios. 34, 153-164. 
[36] Sewell, R.B., Mao, S.J.T., Kawamoto, T. and 
LaRusso, N.F. (1983) J. Lipid Res. 24, 391-401. 
89 
